Compare
Cartesian Therapeutics, Inc. vs Upstream Bio, Inc. vs Xenetic Biosciences, Inc. vs GeoVax Labs, Inc.
| Latest fiscal year | Cartesian Therapeutics, Inc. RNAC | Upstream Bio, Inc. UPB | Xenetic Biosciences, Inc. XBIO | GeoVax Labs, Inc. GOVX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.80M | $2.85M | $2.98M | $2.49M |
| Revenue growth (YoY) | -92.8% | +20.4% | +19.0% | -37.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | -95.2% | -869.3% |
| Net margin | n/m | n/m | -90.1% | -862.3% |
| Net income | -$130.30M | -$143.44M | -$2.68M | -$21.46M |
| EPS (Diluted) | -$5.02 | -$2.66 | -$1.58 | n/a |
| Operating cash flow | -$73.94M | -$133.28M | -$2.29M | -$21.47M |
| Free cash flow | -$79.39M | -$133.44M | n/a | -$21.50M |
| Cash & equivalents | $125.14M | $101.58M | n/a | $3.09M |
| Total assets | $296.41M | $353.77M | $8.36M | $6.34M |
| Total liabilities | $422.65M | $14.00M | $968.0K | $2.52M |
| Shareholders' equity | -$126.24M | $339.77M | $7.40M | $3.83M |
| Return on year-end equity | n/a | -42.2% | -36.2% | -561.2% |
| Shares outstanding | 26.01M | 54.24M | 2.29M | 1.73M |
Revenue, most recent five fiscal years
| Fiscal year | Cartesian Therapeutics, Inc. | Upstream Bio, Inc. | Xenetic Biosciences, Inc. | GeoVax Labs, Inc. |
|---|---|---|---|---|
| Latest | $2.80M Ended 2025-12-31 | $2.85M Ended 2025-12-31 | $2.98M Ended 2025-12-31 | $2.49M Ended 2025-12-31 |
| 1 year earlier | $38.91M Ended 2024-12-31 | $2.37M Ended 2024-12-31 | $2.50M Ended 2024-12-31 | $3.95M Ended 2024-12-31 |
| 2 years earlier | $26.00M Ended 2023-12-31 | $2.38M Ended 2023-12-31 | $2.54M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $1.71M Ended 2022-12-31 | $81.5K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.16M Ended 2021-12-31 | $385.5K Ended 2021-12-31 |